Towards tuberculosis elimination: An action framework for low-incidence countries

European Respiratory Journal

Volumn 45, Issue 4, 2015, Pages 928-952

  Lönnroth, Knut ^a   Migliori, Giovanni Battista ^b   Abubakar, Ibrahim ^c   D'Ambrosio, Lia ^b   De Vries, Gerard ^d   Diel, Roland ^e   Douglas, Paul ^f   Falzon, Dennis ^a   Gaudreau, Marc Andre ^g   Goletti, Delia ^h   González Ochoa, Edilberto R ⁱ   LoBue, Philip ^j   Matteelli, Alberto ^a   Njoo, Howard ^g   Solovic, Ivan ^k   Story, Alistair ^l   Tayeb, Tamara ^m   Van Der Werf, Marieke J ⁿ   Weil, Diana ^a   Zellweger, Jean Pierre ^o   Aziz, Mohamed Abdel ^p   Al Lawati, Mohamed R M ^q   Aliberti, Stefano ^r   De Oñate, Wouter Arrazola ^s   Barreira, Draurio ^t   Bhatia, Vineet ^a   Blasi, Francesco ^u   Bloom, Amy ^v   Bruchfeld, Judith ^w   Castelli, Francesco ^x   Centis, Rosella ^b   Chemtob, Daniel ^y   Cirillo, Daniela M ^z   Colorado, Alberto ^aa   Dadu, Andrei ^ab   Dahle, Ulf R ^ac   De Paoli, Laura ^ad   Dias, Hannah M ^a   Duarte, Raquel ^ae   Fattorini, Lanfranco ^af   Gaga, Mina ^ag   Getahun, Haileyesus ^a   Glaziou, Philippe ^a   Goguadze, Lasha ^ah   Del Granado, Mirtha ^ai   Haas, Walter ^aj   Järvinen, Asko ^ak,al   Kwon, Geun Yong ^am   Mosca, Davide ^an   Nahid, Payam ^ao,ap   Nishikiori, Nobuyuki ^aq   Noguer, Isabel ^ar   O'Donnell, Joan ^as   Pace Asciak, Analita ^at   Pompa, Maria G ^au   Popescu, Gilda G ^av   Cordeiro, Carlos Robalo ^aw   Rønning, Karin ^ac   Ruhwald, Morten ^ax   Sculier, Jean Paul ^ay   Simunović, Aleksandar ^az   Smith Palmer, Alison ^ba   Sotgiu, Giovanni ^bb   Sulis, Giorgia ^a   Torres Duque, Carlos A ^bc   Umeki, Kazunori ^bd   Uplekar, Mukund ^a   Van Weezenbeek, Catharina ^d   Vasankari, Tuula ^ak   Vitillo, Robert J ^be   Voniatis, Constantia ^bf   Wanlin, Maryse ^bg   Raviglione, Mario C ^a   more..

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b IRCCS   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Dept of Immigration and Border Protection ^*  (Australia)

^g PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^h NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

ⁱ INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^k CATHOLIC UNIVERSITY IN RU OMBEROK   (Slovakia)

^l Find and Treat   (United Kingdom)

^m MINISTRY OF HEALTH   (Saudi Arabia)

ⁿ EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^o Swiss Lung Association   (Switzerland)

^p WHO Regional Office for the Eastern Mediterranean   (Egypt)

^q MINISTRY OF HEALTH   (Oman)

^r UNIVERSITY OF MILANO BICOCCA   (Italy)

^s Belgian Lung and Tuberculosis Association   (Belgium)

^t MINISTÉRIO DA SAÚDE   (Brazil)

^u UNIVERSITY OF MILAN   (Italy)

^v UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^w KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^x UNIVERSITY OF BRESCIA   (Italy)

^y MINISTRY OF HEALTH   (Israel)

^z SAN RAFFAELE HOSPITAL   (Italy)

^aa Advocates for Health International   (United States)

^ab WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^ac NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^ad MÉDECINS SANS FRONTIÈRES   (Switzerland)

^ae General Directorate of Health Lisbon   (Portugal)

^af ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^ag Athens Chest Hospital   (Greece)

^ah Red Crescent Societies in Geneva   (Switzerland)

^ai WHO Regional Office for the Americas   (United States)

^aj ROBERT KOCH INSTITUTE   (Germany)

^ak Finnish Lung Health Association   (Finland)

^al HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^am Ministry of Health and Welfare   (South Korea)

^an INTERNATIONAL ORGANIZATION FOR MIGRATION   (Switzerland)

^ao UNIVERSITY OF CALIFORNIA   (United States)

^ap American Thoracic Society   (United States)

^aq The World Health Organization Regional Office for the Western Pacific philippines   (Philippines)

^ar INSTITUTO DE SALUD CARLOS III   (Spain)

^as HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^at Directorate for Health Information and Research Ministry for Energy and Health   (Malta)

^au MINISTRY OF HEALTH   (Italy)

^av Marius Nasta Institute   (Romania)

^aw CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^ax STATENS SERUM INSTITUT   (Denmark)

^ay JULES BORDET INSTITUTE   (Belgium)

^az CROATIAN NATIONAL INSTITUTE OF PUBLIC HEALTH   (Croatia)

^ba HEALTH PROTECTION SCOTLAND   (United Kingdom)

^bb UNIVERSITY OF SASSARI   (Italy)

^bc FUNDACIÓN NEUMOLÓGICA COLOMBIANA   (Colombia)

^bd Japan Ministry of Health Labour and Welfare   (Japan)

^be Caritas Internationalis   (Switzerland)

^bf NICOSIA GENERAL HOSPITAL   (Cyprus)

^bg Fonds des Affections Respiratoires (FARES)   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOGEOGRAPHIC REGION; COOPERATION; DISEASE ELIMINATION; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; FOLLOW UP; FUNDING; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH PROMOTION; HIGH RISK POPULATION; HUMAN; HUMAN RIGHTS; INCIDENCE; INFECTION PREVENTION; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MIGRATION; POLITICAL SYSTEM; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SOCIAL SUPPORT; TREATMENT INDICATION; TUBERCULOSIS; COMMUNICABLE DISEASE CONTROL; DEVELOPED COUNTRY; FEMALE; HEALTH; INTERNATIONAL COOPERATION; MALE; ORGANIZATION; ORGANIZATION AND MANAGEMENT; TUBERCULOSIS, MULTIDRUG-RESISTANT;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; DEVELOPED COUNTRIES; FEMALE; GLOBAL HEALTH; HUMANS; INCIDENCE; INTERNATIONAL COOPERATION; MALE; ORGANIZATIONAL INNOVATION; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84922970030     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00214014     Document Type: Review

References (185)

1. World Health Organization. Global tuberculosis report 2014. WHO/HTM/TB/2014.08. Geneva, World Health Organization, 2014.
2. Blasi F, Barnes PJ, Gaga M, et al. Future directions for the ERS: presidential plans. Eur Respir J 2013; 42: 875-880.
3. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
4. Lönnroth K, Jaramillo E, Williams BG, et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009; 68: 2240-2246.
5. st century: key perspectives, controversies, unresolved issues, and needs. J Infect Dis 2012; 205: Suppl. 2, S141-S146.
6. Story A, Murad S, Roberts W, et al. Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax 2007; 62: 667-671.
7. Ali M. Treating tuberculosis as a social disease. Lancet 2014; 383: 2195.
8. th World Health Assembly. Global strategy and targets for tuberculosis prevention, care and control after 2015. A67/11. Geneva, World Health Organization, 2014.
9. Raviglione MC, Ditiu L. Setting new targets in the fight against tuberculosis. Nat Med 2013; 19: 263.
10. Clancy L, Rieder HL, Enarson DA, et al. Tuberculosis elimination in the countries of Europe and other industrialized countries. Eur Respir J 1991; 4: 1288-1295.
11. European Centre for Disease Prevention and Control. Framework Action Plan to Fight Tuberculosis in the European Union. Stockholm, ECDC, 2008.
12. Centers for Disease Control (CDC). A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 1989; 38: 269-272.
13. Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. Advisory Council for the Elimination of Tuberculosis (ACET). MMWR Recomm Rep 1999; 48; 1-13.
14. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
15. Migliori GB, Zellweger JP, Abubakar I, et al. European Union Standards for Tuberculosis Care. Eur Respir J 2012; 39: 807-819.
16. Hopewell PC, Fair EL, Uplekar M. Updating the International Standards for Tuberculosis Care. Entering the era of molecular diagnostics. Ann Am Thorac Soc 2014; 11: 277-285.
17. World Health Organization. Towards TB elimination: an action framework for low-incidence countries. WHO/HTM/TB/2014.13. Geneva, World Health Organization, 2014.
18. World Health Organization. WHO publications on tuberculosis. http://who.int/tb/publications/en/
19. Lönnroth K, Migliori GB, Raviglione M. Towards tuberculosis elimination in low-incidence countries: reflections from a global consultation. Ann Intern Med 2014; 161: 670-671.
20. World Health Organization. Global TB database. Available from http://who.int/tb/country/data/download/en/ Date last accessed: October 23, 2014.
21. Mor Z, Migliori GB, Althomsons SP, et al. Comparison of tuberculosis surveillance systems in low-incidence industrialised countries. Eur Respir J 2008; 32: 1616-1624.
22. Veen J, Migliori GB, Raviglione M, et al. Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops. Eur Respir J 2011; 37: 950-959.
23. World Health Organization. Standards and benchmarks for tuberculosis surveillance and vital registration systems: checklist and user guide. WHO/HTM/TB/2014.02. Geneva, World Health Organization, 2014.
24. World Health Organization. Assessing tuberculosis under-reporting through inventory studies. WHO/HTM/TB/2012.12. Geneva, World Health Organization, 2012.
25. Voniatis C, Migliori GB, Voniatis M, et al. Tuberculosis elimination: dream or reality? The case of Cyprus. Eur Respir J 2014; 44: 543-546.
26. McKeown T, Record RG. Reasons for the decline of mortality in England and Wales during the nineteenth century. Popul Stud 1962; 16: 94-122.
27. Fairchild A, Oppenheimer M. Public health nihilism vs pragmatism: history, politics, and the control of tuberculosis. Am J Public Health 1998; 88: 1105-1117.
28. Ploubidis GB, Palmer MJ, Blackmore C, et al. Social determinants of tuberculosis in Europe: a prospective ecological study. Eur Respir J 2012; 40: 925-930.
29. Schwartzman K, Oxlade O, Barr RG, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005; 353: 1008-1020.
30. World Health Organization. Draft global strategy and targets for tuberculosis prevention, care and control after 2015. Report by the Secretariat. A67/11. Geneva, World Health Organization, 2014. http://apps.who.int/gb/ebwha/pdf-files/WHA67/A67-11-en.pdf
31. Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City - turning the tide. N Eng J Med 1995; 333: 229-233.
32. Zumla A. The white plague returns to London - with a vengeance. Lancet 2011; 377: 10-11.
33. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis - critical steps for prevention and control. N Engl J Med 2010; 363: 1050-1058.
34. Creswell J, Raviglione M, Ottmani S, et al. Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. Eur Respir J 2011; 37: 1269-1282.
35. Lönnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol 2014; 2: 730-739.
36. Dara M, de Colombani P, Petrova-Benedict R, et al. Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. Eur Respir J 2012; 40: 1081-1090.
37. Arinaminpathy N, Dye C. Health in financial crises: economic recession and tuberculosis in Central and Eastern Europe. J R Soc Interface 2010; 7: 1559-1569.
38. Reeves A, Basu S, McKee M, et al. Social protection and tuberculosis control in 21 European countries, 1995-2012: a cross-national statistical modelling analysis. Lancet Infect Dis 2014; 14: 1105-1112.
39. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
40. Lönnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010; 375: 1814-1829.
41. Zenner D, Southern J, van Hest R, et al. Active case finding for tuberculosis among high-risk groups in low-incidence countries. Int J Tuberc Lung Dis 2013; 17: 573-582.
42. th meeting of low-prevalence countries]. San José, Costa Rica, December 7-8, 2006. Washington, OPS/OMS, 2006.
43. World Health Organization. The World Health Report. Health systems financing: the path to universal coverage. Geneva, World Health Organization, 2010.
44. Collinson S, Ward R. A nurse-led response to unmet needs of homeless migrants in inner London. Br J Nurs 2010; 19: 36-41.
45. Klinkenberg E, Manissero D, Semenza JC, et al. Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. Eur Respir J 2009; 34: 1180-1189.
46. Abubakar I, Stagg HR, Cohen T, et al. Controversies and unresolved issues in tuberculosis prevention and control: a low-burden-country perspective. J Infect Dis 2012; 205: Suppl. 2, S293-S300.
47. nd Edn. New York, Marcel Dekker, 2000; pp. 745-770.
48. World Health Organization. Stop TB Policy Paper. Contributing to health system strengthening. Guiding principles for national tuberculosis programmes. WHO/HTM/TB/2008.400. Geneva, World Health Organization, 2008.
49. Sotgiu G, D'Ambrosio L, Centis R, et al. Availability of anti-tuberculosis drugs in Europe. Eur Respir J 2012; 40: 500-503.
50. Centers for Disease Control and Prevention (CDC). Impact of a shortage of first-line antituberculosis medication on tuberculosis control - United States, 2012-2013. MMWR Morb Mortal Wkly Rep 2013; 62: 398-400.
51. Centers for Disease Control and Prevention (CDC). Extent and effects of recurrent shortages of purified-protein derivative tuberculin skin test antigen solutions - United States, 2013. MMWR Morb Mortal Wkly Rep 2013; 62: 1014-1015.
52. Baussano I, Abbona F, Veljkovic A, et al. Incidenza della tubercolo nella Regione Piemonte nel periodo 2001-2003 [Incidence of tuberculosis in Piedmont Region in the period 2001-2003]. Epidemiol Prev 2008; 32: 85-92.
53. van Hest NA, Story A, Grant AD, et al. Record-linkage and capture-recapture analysis to estimate the incidence and completeness of reporting of tuberculosis in England 1999-2002. Epidemiol Infect 2008; 136: 1606-1616.
54. van Hest NA, Smit F, Baars HW, et al. Completeness of notification of tuberculosis in The Netherlands: how reliable is record-linkage and capture-recapture analysis? Epidemiol Infect 2007; 135: 1021-1029.
55. World Health Organization. Public-private mix for TB care and control: a toolkit. WHO/HTM/TB/2010.12. Geneva, World Health Organization, 2010.
56. Centers for Disease Control and Prevention. Regional Training and Medical Consultation Centers (RTMCCs). Date last updated: November 25, 2013. Date last accessed: October 23, 2014.
57. World Health Organization. A Roadmap for Ensuring Quality Tuberculosis Diagnostics Services within National Laboratory Strategic Plans. Geneva, World Health Organization, 2010.
58. World Health Organization. Framework for conducting reviews of tuberculosis programmes. WHO/HTM/TB/2014.05. Geneva, World Health Organization, 2014.
59. Chemtob D, Leventhal A, Weiler-Ravell D. Screening and management of tuberculosis in immigrants: the challenge beyond professional competence. Int J Tuberc Lung Dis 2003; 7: 959-966.
60. Tollefson D, Bloss E, Fanning A, et al. Burden of tuberculosis in indigenous peoples globally: a systematic review. Int J Tuberc Lung Dis 17: 1139-1150.
61. De Vries G, van Hest NAH, Baars HW, et al. Factors associated with the high tuberculosis case rate in an urban area. Int J Tuberc Lung Dis 2010; 14: 859-865.
62. De Vries G, Aldridge RW, Cayla JA, et al. Epidemiology of tuberculosis in big cities of the European Union and European Economic Area countries. Euro Surveill 2014; 19: pii 20726.
63. Verver S, Veen J. Tuberculosis control and migration. In: Raviglione, ed. TB: a Comprehensive International Approach. New York, Informa Healthcare, 2006.
64. Diel R, Rüsch-Gerdes S, Niemann S. Molecular epidemiology of tuberculosis among immigrants in Hamburg, Germany. J Clin Microbiol 2004; 42: 2952-2960.
65. van Hest NA, Aldridge RW, de Vries G, et al. Tuberculosis control in big cities and urban risk groups in the European Union: a consensus statement. Euro Surveill 2014; 19: pii 20728.
66. Kirby T. Tuberculosis rates unacceptably high in UK cities. Lancet Infect Dis 2013; 13: 836-837.
67. Fortin CF, McDonald PP, Lesur O, et al. Aging and neutrophils: there is still much to do. Rejuvenation Res 2008; 11: 873-882.
68. Uyemura K, Castle SC, Makinodan T. The frail elderly: role of dendritic cells in the susceptibility of infection. Mech Ageing Dev 2002; 123: 955-962.
69. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008; 5: e152.
70. Borgdorff MW, van der Werf MJ, de Haas PE, et al. Tuberculosis elimination in the Netherlands. Emerg Infect Dis 2005; 11: 597-602.
71. Centers for Disease Control and Prevention (CDC). Reported Tuberculosis in the United States, 2012. Atlanta, US Dept of Health and Human Services, CDC, 2013.
72. Schaaf HS, Collins A, Bekker A, et al. Tuberculosis at extremes of age. Respirology 2010; 15: 747-763.
73. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; 2: CD001363.
74. Verma G, Chuck AW, Jacobs P. Tuberculosis screening for long-term care: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2013; 17: 1170-1177.
75. Schwartzman K, Dowdy D. The eye of the beholder: tuberculosis screening for elderly long-term care residents. Int J Tuberc Lung Dis 2013; 17: 1121.
76. Brodie D, Schluger NW. The diagnosis of tuberculosis. Clin Chest Med 2005; 26: 247-271.
77. Haas W. High time to tackle childhood tuberculosis. Euro Surveill 2011; 16: pii 19827.
78. Newton SM, Brent AJ, Anderson S, et al. Paediatric tuberculosis. Lancet Infect Dis 2008; 8: 498-510.
79. Ducomble T, Tolksdorf K, Karagiannis I, et al. The burden of extrapulmonary and meningitis tuberculosis: an investigation of national surveillance data, Germany, 2002 to 2009. Euro Surveill 2013; 18: pii 20436.
80. Sanchini A, Fiebig L, Drobniewski F, et al. Laboratory diagnosis of paediatric tuberculosis in the European Union/European Economic Area: analysis of routine laboratory data, 2007 to 2011. Euro Surveill 2014; 19: pii 20744.
81. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96: 29-35.
82. Bourdin Trunz B, Fine PE, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367: 1173-1180.
83. Manissero D, Lopalco PL, Levy-Bruhl D, et al. Assessing the impact of different BCG vaccination strategies on severe childhood TB in low-intermediate prevalence settings. Vaccine 2008; 26: 2253-2259.
84. Guthmann JP, Chauvin P, Le Strat Y, et al. Family history of immigration from a tuberculosis endemic country and low family income are associated with a higher BCG vaccination coverage in Ile-de-France region, France. Vaccine 2013; 31: 5666-5671.
85. Nguipdop-Djomo P, Mangtani P, Pedrazzoli D, et al. Uptake of neonatal BCG vaccination in England: performance of the current policy recommendations. Thorax 2014; 69: 87-89.
86. Tuberculosis Coalition for Technical Assistance (TBCTA). Patient Centered Approach Strategy. The Hague, TBCTA, 2011.
87. World Health Organization. Guidance on ethics of tuberculosis prevention, care and control. WHO/HTM/TB/2010.16. Geneva, World Health Organization, 2010.
88. Lönnroth K, Glaziou P, Weil D, et al. Beyond UHC: monitoring health and social protection coverage in the context of tuberculosis care and prevention. PLoS Med 2014; 11: e1001693.
89. Lönnroth K, Jaramillo E, Williams BG, et al. Tuberculosis - the role of risk factors and social determinants. In: Blas E, Sivasankara Kurup A, eds. Priority Public Health Conditions: From Learning to Action on Social Determinants of Health. Geneva, World Health Organization, 2010.
90. World Health Organization. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. WHO/HTM/TB/2012.1. Geneva, World Health Organization, 2012.
91. World Health Organization, International Union against Tuberculosis and Lung Disease. A WHO/The Union Monograph on TB and Tobacco Control. WHO/HTM/TB/2007.390. Geneva, World Health Organization, 2008.
92. Rehm J, Samokhvalov AV, Popova S, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review? BMC Public Health 2009; 9: 450.
93. World Health Organization. Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach. WHO/HTM/TB/2008.404. Geneva, World Health Organization, 2008.
94. Chemtob D, Levy A. Rationale and staff evaluation of using a "therapeutic milieu" for substance users within a tuberculosis ward. Subst Use Misuse 2009; 44: 672-683.
95. World Health Organization, International Union against Tuberculosis and Lung Disease. Collaborative framework for care and control of tuberculosis and diabetes. WHO/HTM/TB/2011.15. Geneva, World Health Organization, 2011.
96. World Health Organization. Guideline: Nutritional care and support for people with tuberculosis. Geneva, World Health Organization, 2013.
97. nd Edn. WHO/HTM/TB/2014.03. Geneva, World Health Organization, 2014.
98. World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec 2004; 79: 27-38.
99. World Health Organization. Health of Migrants. Report by the Secretariat. A61/12. Geneva, World Health Organization, 2008.
100. st century policy-making. PLoS Med 2011; 8: e1001034.
101. Arshad S, Bavan L, Gajari K, et al. Active screening at entry for tuberculosis among new immigrants: a systematic review and meta-analysis. Eur Respir J 2010; 35: 1336-1345.
102. Dara M, Gushulak BD, Posey DL, et al. The history and evolution of immigration medical screening for tuberculosis. Expert Rev Anti Infect Ther 2013; 11: 137-146.
103. Sandgren A, Schepisi MS, Sotgiu G, et al. Tuberculosis transmission between foreign- and native-born populations in the EU/EEA: a systematic review. Eur Respir J 2014; 43: 1159-1171.
104. Fattorini L, Mustazzolu A, Piccaro G, et al. Drug-resistant tuberculosis among foreign-born persons in Italy. Eur Respir J 2012; 40: 497-500.
105. Moore-Gillon J, Davies PD, Ormerod LP. Rethinking TB screening: politics, practicalities and the press. Thorax 2010; 65: 663-665.
106. Helbling P, Medinger C, Altpeter E, et al. Outcome of treatment of pulmonary tuberculosis in Switzerland in 1996. Swiss Med Wkly 2002; 132: 517-522.
107. Lambregts-van Weezenbeek CS, Sebek MM, van Gerven PJ, et al. Tuberculosis contact investigation and DNA fingerprint surveillance in The Netherlands: 6 years' experience with nation-wide cluster feedback and cluster monitoring. Int J Tuberc Lung Dis 2003; 7: Suppl 3, S463-S470.
108. Dahle UR, Eldholm V, Winje BA, et al. Impact of immigration on the molecular epidemiology of Mycobacterium tuberculosis in a low-incidence country. Am J Respir Crit Care Med 2007; 176: 930-935.
109. Jasmer RM, Hahn JA, Small PM, et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999; 130: 971-978.
110. Goldblatt D, Rorman E, Chemtob D, et al. Molecular epidemiology and mapping of tuberculosis in Israel: do migrants transmit the disease to locals? Int J Tuberc Lung Dis 2014; 18: 1085-1091.
111. Kamper-Jorgensen Z, Andersen AB, Kok-Jensen A, et al. Migrant tuberculosis: the extent of transmission in a low burden country. BMC Infect Dis 2012; 12: 60.
112. Borgdorff MW, Nagelkerke N, van Soolingen D. Analysis of tuberculosis transmission between nationalities in the Netherlands in the period 1993-1995 using DNA fingerprinting. Am J Epidemiol 1998; 147: 187-195.
113. Codecasa LR, Ciconali G, Mazzola E, et al. Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal. Eur Respir J 2015; 45: 292-294.
114. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
115. D'Ambrosio L, Tadolini M, Dupasquier S, et al. ERS/WHO tuberculosis consilium: reporting of the initial 10 cases. Eur Respir J 2014; 43: 286-289.
116. Bernard C, Brossier F, Sougakoff W, et al. A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. Euro Surveill 2013; 18: pii 20555.
117. Liu Y, Painter JA, Posey DL, et al. Estimating the impact of newly arrived foreign-born persons on tuberculosis in the United States. PLoS One 2012; 7: e32158.
118. World Health Organization. Systematic screening for active tuberculosis. Principles and recommendations. WHO/HTM/TB/2013.04. Geneva, World Health Organization, 2013.
119. Kranzer K, Afnan-Holmes H, Tomlin K, et al. The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis 2013; 17: 432-446.
120. Walter ND, Jasmer RM, Grinsdale J, et al. Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective. Clin Infect Dis 2008; 46: 103-106.
121. World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva, World Health Organization, 2015.
122. Paquette K, Cheng MP, Kadatz MJ, et al. Chest radiography for active tuberculosis case finding in the homeless: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2014; 18: 1231-1236.
123. De Vries G, Baars HW, Sebek MM, et al. A transmission classification model to determine place and time of infection of tuberculosis cases in an urban area. J Clin Microbiol 2008; 46: 3924-3930.
124. Kamper-Jørgensen Z, Andersen AB, Kok-Jensen A, et al. Characteristics of non-clustered tuberculosis in a low burden country. Tuberculosis 2012; 92: 226-231.
125. Heldal E, Docker H, Caugant DA, et al. Pulmonary tuberculosis in Norwegian patients. The role of reactivation, re-infection and primary infection assessed by previous mass screening data and restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 2000; 4: 300-307.
126. Sotgiu G, Bourdin Trunz B, Migliori GB, et al. Childhood tuberculosis outbreaks in EU/EEA: a systematic review. Eur Respir J 2013; 42: Suppl. 57, P1610.
127. Migliori GB, Centis R, D'Ambrosio L, et al. Impact and management of TB childhood outbreaks in EU/EEA. Eur Respir J 2013; 42: Suppl. 57, 3532.
128. European Centre for Disease Prevention and Control. Investigation and control of tuberculosis incidents affecting children in congregate settings. Stockholm, ECDC, 2013. www.ecdc.europa.eu/en/publications/Publications/guidance-investigation-control-tb-incidents-children-in-congregate-settings.pdf
129. Lai RP, Nakiwala JK, Meintjes G, et al. The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 2013; 43: 1995-2002.
130. Ferrara G, Murray M, Winthrop K, et al. Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs. Curr Opin Pulm Med 2012; 18: 233-240.
131. Moore-Gillon J. Diabetes and tuberculosis: a gathering storm? Thorax 2010; 65: 571-572.
132. Pareek M, Watson JP, Ormerod LP, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011; 11: 435-444.
133. Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 2014; 91: 56-64.
134. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149: 689-697.
135. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
136. Horsburgh CRJr, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010; 137: 401-409.
137. Colson PW, Hirsch-Moverman Y, Bethel J, et al. Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada. Int J Tuberc Lung Dis 2013; 17: 473-479.
138. Li J, Munsiff SS, Tarantino T, et al. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis 2010; 14: e292-e297.
139. Bibi H, Weiler-Ravell D, Shoseyov D, et al. Compliance to treatment of latent tuberculosis infection in a region of Israel. Isr Med Assoc J 2002; 4: 13-16.
140. Goswami ND, Gadkowski LB, Piedrahita C, et al. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health 2012; 12: 468.
141. Trajman A, Long R, Zylberberg D, et al. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis 2010; 14: 551-559.
142. Kan B, Kalin M, Bruchfeld J. Completing treatment for latent tuberculosis: patient background matters. Int J Tuberc Lung Dis 2013; 17: 597-602.
143. Garie KT, Yassin MA, Cuevas LE. Lack of adherence to isoniazid chemoprophylaxis in children in contact with adults with tuberculosis in Southern Ethiopia. PLoS One 2011; 6: e26452.
144. Cruz AT, Starke JR. Twice-weekly therapy for children with tuberculosis infection or exposure. Int J Tuberc Lung Dis 2013; 17: 169-174.
145. Sarivalasis A, Bodenmann P, Langenskiold E, et al. High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton. Swiss Med Wkly 2013; 143: w13860.
146. Schaaf HS, Gie RP, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002; 109: 765-771.
147. Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis 2014; 18: 912-918.
148. World Health Organization. Early detection of tuberculosis: an overview of approaches, guidelines and tools. WHO/HTM/STB/PSI/2011.21. Geneva, World Health Organization, 2011.
149. World Health Organization. Recommendations for investigating the contacts of persons with infectious tuberculosis in low- and middle-income countries. WHO/HTM/TB/2012.9. Geneva, World Health Organization, 2012.
150. Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010; 36: 925-949.
151. World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. WHO/HTM/TB/2009.419. Geneva, World Health Organization, 2009.
152. World Health Organization. Guidelines for the control of tuberculosis in prisons. WHO/TB/98.250. Geneva, World Health Organization, 1998.
153. rd Edn. WHO/HTM/TB/2008.399. Geneva, World Health Organization, 2008.
154. World Health Organization. Tuberculosis care and control in refugee and displaced populations. WHO/HTM/TB/2007.377. Geneva, World Health Organization, 2007.
155. World Health Organization. Disease outbreaks. http://www.who.int/topics/disease-outbreaks/en/
156. van't Hoog AH, Onozaki I, Lönnroth K. Choosing algorithms for TB screening: a modelling study to compare yield, predictive value and diagnostic burden. BMC Infect Dis 2014; 14: 532.
157. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
158. Fears R, Kaufmann S, Ter Meulen V, et al. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control. Tuberculosis 2010; 90: 182-187.
159. Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
160. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, World Health Organization, 2008.
161. Carvalho AC, Migliori GB, Cirillo DM. Tuberculosis in Europe: a problem of drug resistance or much more? Expert Rev Respir Med 2010; 4: 189-200.
162. Pontali E, Matteelli A, Migliori GB. Drug-resistant tuberculosis. Curr Opin Pulm Med 2013; 19: 266-272.
163. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
164. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
165. rd Edn. The Hague, TB CARE I, 2014. www.who.int/tb/publications/ISTC-3rdEd.pdf
166. Dheda K, Migliori GB. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 2012; 379: 773-775.
167. Laniado-Laborin R, Kiy R, Spanevello A, et al. Declaration on palliative care for MDR/XDR-TB. Int J Tuberc Lung Dis 2012; 16: 1418-1419.
168. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
169. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
170. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
171. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
172. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
173. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013; 12: 388-404.
174. World Health Organization. Introduction and rational use of new drugs/regimens for the treatment of tuberculosis in countries. Date last accessed: October 23, 2014.
175. European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm, ECDC, 2013.
176. World Health Organization. Understanding and using tuberculosis data. WHO/HTM/TB/2014.09. Geneva, World Health Organization, 2014.
177. Nunes C. Tuberculosis incidence in Portugal: spatiotemporal clustering. Int J Health Geogr 2007; 6: 30.
178. Moonan PK, Ghosh S, Oeltmann JE, et al. Using genotyping and geospatial scanning to estimate recent Mycobacterium tuberculosis transmission, United States. Emerg Infect Dis 2012; 18: 458-465.
179. Jia ZW, Jia XW, Liu YX, et al. Spatial analysis of tuberculosis cases in migrants and permanent residents, Beijing, 2000-2006. Emerg Infect Dis 2008; 14: 1413-1419.
180. World Health Organization. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient. Geneva, World Health Organization, 2012.
181. Frick M, Jiménez-Levi E. 2013 Report on Tuberculosis Research Funding Trends, 2005-2012. New York, Treatment Action Group, 2013.
182. Migliori GB, Sotgiu G. Treatment of tuberculosis: have we turned the corner? Lancet 2012; 380: 955-957.
183. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014; 44: 1412-1417.
184. Evans TG, Brennan MJ, Barker L, et al. Preventive vaccines for tuberculosis. Vaccine 2013; 31: Suppl. 2, B223-B226.
185. Dara M, Acosta CD, Rusovich V, et al. Bacille Calmette-Guerin vaccination: the current situation in Europe. Eur Respir J 2014; 43: 24-35.